Safoni, ImmuNext to Team Up to Develop INX-021 Antibody for Autoimmune Disorders

Sanofi will work with ImmuNext to develop INX-021, a CD40L monoclonal antibody designed to suppress overactive cell signals associated with autoimmune disorders, including lupus and multiple sclerosis. Under the agreement, Sanofi will have an exclusive license to further develop and commercialize INX-021, a synthetic antibody from ImmuNext that is now in preclinical…

Selexis to Equip ImmuNext with Cells Needed for Antibody That May Treat Lupus

Selexis recently signed an agreement that grants ImmuNext access to the company’s cell lines in order to advance an antibody being developed to treat systemic lupus erythematosus and other autoimmune conditions. Geneva-based Selexis focuses on the development of specific mammalian cells, called CHO-K1, which are adapted to growth in suspension. The cell lines which…